reports
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone...
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are ...
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients a...
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP) PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation anormale de nouvelle matière osseuse (ossification hétérotopique ou OH) chez l’adulte et l’enfant atteints de fibrodysplasie ossifiante progressive (FOP), par rapport au placebo, en conséquence, l'étude sera clôturée. Le mé...
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-...
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors — First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of its global Phase I clinical development program for HMPL-A251, a first-in-class PI3K/PIKK-HER2 Antibody-Targeted Therapy Conjugate (“ATTC”) co...
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi...
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des thérapies d’immuno-oncologie de nouvelle génération. A propos d’Ipsen Nous sommes un groupe biopharmaceutique mondial focalisé sur la mise au point de médicaments innovants pour les patients dans trois domaines thérapeutiques : l’Oncologie, les Maladies Rare...
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncolog...
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 year...
- Franc Gregori
- Lala Gregorek
HUTCHMED: Pipeline potential underpins long-term growth prospects
HUTCHMED’s recent R&D update highlighted multiple catalysts expected over the next 12-24 months, including the launches of new products and regulatory decisions on new indications for existing products which will be key for near- and mid-term revenue growth in China. Ex-China, partner AstraZeneca has guided towards Phase III SAFFRON top-line data in H126, with savolitinib remaining on track to become HUTCHMED’s second global asset. Longer-term, the proprietary ATTC platform offers significant po...
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Moody's Ratings affirms Eli Lilly's Aa3 rating; revises outlook to pos...
Moody's Ratings (Moody's) affirmed the ratings of Eli Lilly and Company ("Lilly") including the Aa3 senior unsecured notes ratings and long-term issuer rating, the (P)Aa3 senior unsecured shelf and medium term note program ratings, and the Prime-1 short-term commercial paper rating. At the same time...
- Carol Dou Xiao Qin
- Sunny Chen
China Healthcare Bi-Weekly: Short-term Profit-taking Masks Solid Funda...
China healthcare stocks were relatively weak during the first two weeks of Dec 25 as investors took profits, particularly for internet healthcare and drug innovator names. Fundamentals remain solid, supported by the new commercial insurance policy, lower costs of capital, and robust pipelines. Despite rising competition in areas like generics, GLP-1 drugs and surgical robots, companies continue to advance towards sustainable growth. Maintain OVERWEIGHT. Our top picks are BeOne Medicines, Hansoh ...
00241 ALIBABA HEALTH INFORMATION TECHNOLOGY LTD.
01177 SINO BIOPHARMACEUTICAL LIMITED
X2S SINOPHARM GROUP CO. LTD. CLASS H
HCM HUTCHISON CHINA MEDITECH LTD SPONSORED ADR
3933 THE UNITED LABORATORIES INTE
2877 CHINA SHINEWAY PHARMACEUTICA
01801 HUTCHISON CHINA MEDITECH LIMITED
1833 INNOVENT BIOLOGICS INC.
300760 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED
603882 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO. LTD. CLASS A
1093 GUANGZHOU KINGMED DIAGNOSTICS GROUP CO. LTD. CLASS A
603259 CSPC PHARMACEUTICAL GROUP LTD
2269 WUXI APPTEC CO. LTD. CLASS A
3692 WUXI BIOLOGICS (CAYMAN) INC.
06160 HANSOH PHARMACEUTICAL GROUP
300244 BEIGENE LTD.
WUXI APPTEC CO. LTD. CLASS H
DIAN DIAGNOSTICS GROUP CO
IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025
IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from December 1st to December 05th 2025 Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150200124,05000AQEUIPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150831123,81540CEUXIPSEN549300M6SGDPB4Z94P1101/12/2025FR0...
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 49 - 2025 Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 01 Décembre au 05 Décembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code identifiant de l'instrument financier Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d'acquisition Code identifiant marché IPSEN 549300M6SGDPB4Z94P11 01/12/2025 FR0010259150 200 124,05000 AQEU IPSEN 549300M...
Ipsen - November 2025 - Monthly information relative to the total numb...
Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)30 November 2025 83,814,526 Gross total* of ...
Ipsen - Novembre 2025 - Information mensuelle relative au nombre total...
Ipsen - Novembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital social Nombre total de droits de vote (1) 30 novembre...
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug Li...
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2026 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. In addition, TAZVERIK® will be included in the first ...
Ipsen provides update on legacy of Henri Beaufour
Ipsen provides update on legacy of Henri Beaufour PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative of the founding family who passed away on November 28, 2025. This transfer is expected to take place in early 2026 after having obtained the required regulatory approvals*. Beech Tree is the holding company owning directly and indirectly the stake in Ipsen shares of Mr. Beaufour. Alasol Fo...
Ipsen apporte des précisions sur l'héritage d'Henri Beaufour
Ipsen apporte des précisions sur l'héritage d'Henri Beaufour PARIS, FRANCE, 5 décembre 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) a été informé que les actions de Beech Tree seront transférées à la Fondation Alasol, conformément aux souhaits de M. Henri Beaufour, membre du Conseil d'administration d'Ipsen et représentant de la famille fondatrice, décédé le 28 novembre 2025. Ce transfert devrait avoir lieu début 2026, après obtention des autorisations réglementaires nécessaires (*). Beech Tree est la société holding qui détient directement et indirectement la participation de M. Beaufour dans...
IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025
IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from November 24th to November 28th 2025 Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1124/11/2025FR0010259150300128,00000AQEUIPSEN549300M6SGDPB4Z94P1124/11/2025FR00102591501000127,96010CEUXIPSEN549300M6SGDPB4Z94P1124/11/2025...
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 48 - 2025 Présentation agrégée par jour et par marchéDéclaration des transactions sur actions propres réalisées du 24 Novembre au 28 Novembre 2025 Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marchéIPSEN549300M6SGDPB4Z94P1124/11/2025FR0010259150300128,00000AQEUIPSEN549300M6SGDPB4Z94P1124/11/2025FR00102591501000127,96010C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.